Maxcyte (MXCT) Research & Development (2020 - 2026)

Maxcyte (MXCT) has 7 years of Research & Development data on file, last reported at $3.9 million in Q1 2026.

• Research & Development for Q1 2026 came in at $3.9 million, down 34.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.8 million (down 12.47% YoY), and the FY2025 annual result was $20.8 million, down 6.32% from the prior year.
• Research & Development rose to $3.9 million in Q1 2026 per MXCT's latest filing, from $3.3 million in the prior quarter.
• Over five years, Research & Development peaked at $6.7 million in Q1 2024 and troughed at $3.3 million in Q4 2025.
• A 5-year average of $5.3 million and a median of $5.6 million in 2024 frame the typical range for Research & Development.
• On a YoY basis, Research & Development climbed as much as 93.86% in 2022 and fell as far as 38.03% in 2022.
• A 5-year view of Research & Development shows it stood at $5.7 million in 2022, then rose by 2.0% to $5.8 million in 2023, then decreased by 21.02% to $4.6 million in 2024, then fell by 27.72% to $3.3 million in 2025, then gained by 15.65% to $3.9 million in 2026.
• Business Quant data shows MXCT's Research & Development at $3.9 million in Q1 2026, $3.3 million in Q4 2025, and $5.3 million in Q3 2025.